Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01670994 · ClinicalTrials.gov registry record · Phase 1
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Altor BioScience.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01670994 is a Phase 1 study that was terminated before completion, run by Altor BioScience. The registered enrollment target is 6 participants.
The verdict
NCT01670994, a Phase 1 study, was terminated before completion, sponsored by Altor BioScience.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 in patients who have relapsed or refractory multiple myeloma.
Interventions
- BIOLOGICAL ALT-801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-08-14 |
| Est. Completion | 2015-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01670994
The ClinicalTrials.gov registry entry for NCT01670994 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altor BioScience, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALT-801 is the first listed.
NCT01670994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01670994 about?
NCT01670994 is a clinical study titled "QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma". This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 in patients who have relapsed or refractory multiple myeloma.
What is the current status of trial NCT01670994?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2012-08-14. Estimated completion is 2015-09-09.
What interventions are being tested in trial NCT01670994?
The interventions under investigation include: ALT-801 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01670994?
This trial is sponsored by Altor BioScience, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.